Thoracic Neoplasms Clinical Trial
Official title:
mHealth ALIBIRD: A Digital Health Care Model (Analysis of the Applicability of an m-Health Platform and Its Impact on the Follow-up of Patients With Cancer: Pilot Study in a Sample of Patients With Advanced Non-small Cell Carcinoma)
NCT number | NCT05770869 |
Other study ID # | mHA |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 5, 2021 |
Est. completion date | October 28, 2022 |
The aim of this pilot study was to evaluate the feasibility and acceptability of the ALIBIRD platform, a new mobile health (mHealth) application prototype design for personalized and remote support on the follow-up of cancer patients. The ALIBIRD platform is a mHealth intervention that tracks PROs, improving symptom control and allowing real-time feedback, and provides personalized recommendations and educational content, promoting empowerment and encourage healthy lifestyle behaviors in patients with thoracic neoplasms in active treatment.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 28, 2022 |
Est. primary completion date | October 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients diagnosed with thoracic neoplasms, histologically or cytologically confirmed. - < 18 years. - Eastern Cooperative Oncology Group (ECOG) performance status = 2. - Patients receiving cancer treatment: chemotherapy, chemotherapy-immunotherapy, immunotherapy or biological therapy. - Patients with internet access and intermediate level in the use of technology (Smartphone, mobile applications, wearable) - Signed informed consent. Exclusion Criteria: - Patients with symptomatic brain metastases. - Patients with neurological impairment, dementia or psychiatric disorders. - Patients unable to follow the protocol due to psychological, social or geographic reasons. |
Country | Name | City | State |
---|---|---|---|
Spain | Servicio de Oncología. Hospital Infanta Sofía | San Sebastián De Los Reyes | Madrid |
Lead Sponsor | Collaborator |
---|---|
Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares | Hospital Infanta Sofia, IMDEA Food, Instituto de Investigación en Ciencias de la Alimentación (CIAL), Universidad Politecnica de Madrid |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Usability and feasibility assesment | Changes in Satisfaction System Usability Scale (SUS) | week 1 to 28 | |
Secondary | Changes in Mediterranean Diet Serving Score (MDSS) | Mediterranean adherence assesment | Week 1 to 28 | |
Secondary | Changes in Quality of life ( European Quality of Life-5 Dimensions 5 Levels questionnaire,EQ-5D-5L) from baseline | Quality of life assesment. The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. In the VAS the individual scores his or her health between two extremes, 0 and 100, the worst and best state of health imaginable. |
Week 1 to 28 | |
Secondary | Changes in physical activity (International Physical Activity Questionnaire,PAQ) | Physical activity assesment | Week 1 to 28 | |
Secondary | Changes in sleep (Pittsburg questionnaire) | Sleep assesment | Week 1 to 28 | |
Secondary | Changes in Quality of life ( The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13, EORTC QLQ-LC-13) | Quality of life assesment. The LC13 covers 13 typical symptoms of lung cancer patients, such as coughing, pain, dyspnea, sore mouth, peripheral neuropathy, and hair loss. questions along 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning) and nine symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) All items are scored from 1 to 4 in relation to the presence of the symptom: not at all, a little, quite a bit, very much. | Week 1 to 28 | |
Secondary | Changes in toxicity (Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events, PRO-CTAE questionnaire) | Toxicity assesment | week 1 to 28 | |
Secondary | Changes is Hospital Anxiety and Depression Questionnaire (HADs) from baseline | Emotional status assesment. This is a scale containing two subscales with 7 anxiety symptoms (HADS-A) and 7 depression symptoms (HADS-D).
The items are scored on a 4-point Likert frequency scale (0-3) with a total score ranging from 0 to 21 for each subscale, where a higher score is indicative of greater symptom severity. |
Week 1 to 28 | |
Secondary | Changes in Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) from baseline | Sexuality assesment | Week 1 to 28 | |
Secondary | Changes is medication adherence (MMAS-8 questionnaire) | Medication adherence assesment | Week 1 to 28 | |
Secondary | Changes in belief in medication (Beliefs about Medicines Questionnaire,BMQ) | Belief in medication assesment | Week 1 to 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04741958 -
Role of Ultrasound Guided Peripheral Thoracic Tumors
|
N/A | |
Recruiting |
NCT04556344 -
Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer
|
N/A | |
Terminated |
NCT03306693 -
Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers
|
N/A | |
Completed |
NCT04751552 -
Erector Spinae Block for Thoracoscopic Surgery
|
N/A | |
Not yet recruiting |
NCT06104774 -
The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery
|
N/A | |
Active, not recruiting |
NCT04589247 -
Improving Cancer Symptom Management
|
||
Not yet recruiting |
NCT04133337 -
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
|
Phase 1/Phase 2 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Completed |
NCT02188563 -
A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers
|
N/A | |
Completed |
NCT03134872 -
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
|
Phase 3 | |
Not yet recruiting |
NCT04371796 -
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
|
Phase 2 | |
Completed |
NCT00437372 -
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
|
Phase 1 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04862780 -
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04776447 -
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
|
Phase 2 | |
Recruiting |
NCT05988736 -
Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients.
|
N/A | |
Not yet recruiting |
NCT06376084 -
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
|
||
Active, not recruiting |
NCT04222972 -
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 |